The apoptosis protector, bcl-2 protein, is downregulated in bile duct epithelial cells of human liver allografts

Journal of Hepatology

Volumn 26, Issue 3, 1997, Pages 535-542

  Gapany, Christophe ^a   Ming, Zhao ^a   Arthur, Zimmermann ^a  

^a NONE

Author keywords

allografts; apoptosis; bcl 2; bile ducts; cirrhosis; liver

Indexed keywords

ALLOGRAFT; APOPTOSIS; ARTICLE; BILE DUCT; BILIARY CIRRHOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS;

EID: 0343487611     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80418-7     Document Type: Article

References (46)

1. Nawaz S, Fennell RH. Apoptosis of bile duct epithelial cells in hepatic allograft rejection. Histopathology. 25:1994;137-142.
2. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA. 82:1985;7439-7443.
3. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. Cloning the chromosomal breakpoint of t(14;18) human lymphomas. Cell. 41:1985;889-906.
4. Tsujimoto Y, Gorham J, Cossmann J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 229:1985;1390-1393.
5. Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene. 2:1987;3-7.
6. Aisenberg AC, Wilkes BM, Jaccobson JO. The bcl-2 gene is rearranged in many difusse B-cell lymphomas. Blood. 71:1988;969-972.
7. Vaux DL, Cory S, Adam JM. bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre B cells. Nature. 335:1988;440-442.
8. Chen-Levy Z, Nourse J, Cleary ML. The bcl-2 candidate proto-oncogene product is a 24 kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol. 9:1989;701-710.
9. Zhao M, Zhang NX, Economou M, Blaha I, Laissue JA, Zimmermann A. Immunohistochemical detection of bcl-2 protein in liver lesions. Histopathology. 25:1994;237-245.
10. Hockenbergy DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 88:1991;6961-6965.
11. Lu QL, Poulsom R, Wong L, Hanby AM. bcl-2 expression in adult and embryonic nonhematopoietic tissues. J Pathol. 169:1993;431-437.
12. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissue suggests a role in morphogenesis. Am J Pathol. 142:1993;743-753.
13. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
14. Terada T, Nakanuma Y. Detection of apoptosis and expression of apoptosis-related proteins during human intrahepatic bile duct development. Am J Pathol. 146:1995;67-74.
15. Charlotte F, L'Herminé A, Martin N, Geleyen Y, Nollett M, Gaulard P, Zafrani ES. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol. 144:1994;460-465.
16. Benedetti A, Jezequel AM, Orlandi F. Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver. J Hepatol. 7:1988;319-324.
17. Zhao M, Zhang NX, Du ZY, Laissue JA, Zimmermann A. Three types of liver cell dysplasia in small cirrhotic nodules ar distinguishable by karyometry and PCNA labelling, and their features resemble distinct grades of hepatocellular carcinoma. Histol Histopath. 9:1994;73-83.
18. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol. 170:1993;1-8.
19. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
20. Snover DC, Sibley RK, Freese DK, Sharp HL, Bloomer JR, Najarian JS, Ascher NL. Orthotopic liver transplantation: a pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection. Hepatology. 4:1984;1212-1222.
21. Snover DC, Freese DK, Sharp HL, Bloomer JR, Najarian JA, Ascher NL. Liver allograft rejection. An analysis of the use of biopsy in determining outcomes of rejection. Am J Surg Pathol. 11:1987;1-10.
22. Kemnitz J, Ringe B, Cohnert TR, Gubernatis G, Choritz H, Georgii A. Bile duct injury as part of diagnostic criteria for liver allograft rejection. Hum Pathol. 20:1989;132-143.
23. Gupta SD, Hudson M, Burroughs AK, Morris R, Rolles K, Amlot P, Scheuer PJ, Dhillon AP. Grading of cellular rejection after orthotopic liver transplantation. Hepatology. 21:1995;46-57.
24. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
25. Schmid M, Flury R, Bühler H, Havelka J, Grob PJ, Heitz PU. Chronic viral hepatitis B and C: an argument against the conventional classification of chronic hepatitis. Virchows Arch. 425:1994;221-228.
26. Gelb AB, Kamel OW, LeBrun DP, Warnke RA. Estimation of tumor growth fractions in archival formalin-fixed, paraffin-embedded tissues using two anti-PCNA/cyclin monoclonal antibodies. Factors affecting reactivity. Am J Pathol. 141:1992;1453-1458.
27. Coltrera MD, Zarbo RJ, Sakr WA, Grown AM. Markers for dysplasia of the upper aerodigestive tract. Suprabasal expression of PCNA, p53, and CK 19 in alcohol-fixed, embedded tissue. Am J Pathol. 141:1992;817-825.
28. Galand P, Degraef C. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labeling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 22:1989;383-392.
29. Garcia RL, Coltrera MD, Grown AM. Analysis of proliferative grade using anti PCNA/cyclin monoclonal antibodies in fixed embedded tissues. Am J Pathol. 135:1989;733-739.
30. Francis SE, Holt CM, Gadson PA, Angelini GD. Another cautionary note on the use of PCNA. J Pathol. 166:1992;418.
31. Koukoulis G, Rayner A, Tan KC, Williams R, Portmann B. Immunolocalization of regenerating cells after submassive liver necrosis using PCNA staining. J Pathol. 166:1992;359-368.
32. Yu CCW, Hall PA, Fletcher CDM, Camplejohn RS, Waseem NH, Lane DP, Levison DA. Haemangio-pericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferative cell nuclear antigen (PCNA). Histopathology. 19:1992;29-33.
33. Zhao D, Zimmermann A, Wheatley AM. Morphometry of the liver after liver transplantation in the rat: Significance of an intact arterial supply. Hepatology. 17:1993;310-317.
34. Tessitore L, Valente G, Bonelli G, Costelli P, Baccino FM. Regulation of cell turnover in the livers of tumor bearing rats: occurrence of apoptosis. Int J Cancer. 44:1989;697-700.
35. Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology. 21:1995;1725-1741.
36. Benedetti A, Jézéquel AM, Orlandi FA. A quantitative evaluation of apoptotic bodies in rat liver. Liver. 8:1988;172-177.
37. Searle J, Harmon BV, Bishop CJ, Kerr JFR. The significance of cell death by apoptosis in hepatobiliary disease. J Gastroenterol Hepatol. 2:1987;77-96.
38. Afford SC, Hübscher S, Strain AJ, Adams DH, Neuberger JM. Apoptosis in the human liver during allograft rejection and end-stage liver disease. J Pathol. 176:1995;373-380.
39. Allen PD, Bustin SA, Macey MG, Johnston DH, Williams NS, Newland AC. Programmed cell death (apoptosis) in immunity and haematological neoplasia. Br J Biomed Sci. 50:1993;135-149.
40. Lockshin RA, Zakeri ZF. Programmed cell death: New thoughts and relevance to aging. J Gerontol. 45:1990;B 135-140.
41. Martin SJ. Apoptosis: suicide, execution or murder? Trends Cell Biol. 3:1993;141-144.
42. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
43. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CD, Harris A, Gatter KC, Mason DY. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med. 329:1993;690-694.
44. Merritt AJ, Potten CS, Watson AJM, Loh DY, Nakayama KI, Nakayama K, Hickman JA. Differential expression of bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci. 108:1995;2261-2271.
45. Majno G, Joris I. Apoptosis, oncosis, and necrosis, An overview of cell death. Am J Pathol. 146:1995;3-15.
46. Bernauau D, Feldmann G, Degott C, Gisselbrecht C. Ultrastructural lesions of bile ducts in primary biliary cirrhosis. A comparison with the lesions observed in graft versus host disease. Hum Pathol. 12:1981;782-793.